Corning has penned separate collaboration agreements with Italy-based Stevanato Group and Germany-headquartered Gerresheimer to supply glass packaging for injectable drugs.
Pfizer Inc. has awarded Catalent Pharma Solutions the long-term manufacturing contract for a smaller version of its over-the-counter (OTC) painkiller Advil (ibuprofen).
Elite Pharmaceuticals has halted trials of its reformulated opioid painkiller SequestOx (naltrexone and oxycodone hydrochloride) after disappointing bioequivalence data from a study testing the drug in combination with a high fat meal.
Researchers at London, UK-based Imperial College are developing a technology to transport drugs directly to the lungs of pulmonary arterial hypertension (PAH) patients.
French technology firm Cellnovo has selected Flex Ltd to build a production line in Romania, to manufacture insulin cartridges for its diabetes management system.
The team behind a microneedle patch designed to administer influenza vaccines say it has increased thermostability compared to needle and syringe immunisation methods.
Pfizer is building a $200m (€179m) R&D centre in Chesterfield, Missouri at which it will consolidate biotherapeutics process development operations in the region.
Lonza expects to complete its $5.5bn (€5.2bn) takeover of Capsugel SA in the next few days having secured approval from competition authorities around the world.
Inovio Pharmaceuticals has started Phase III trials of its DNA-based human papillomavirus therapy VGX-3100 after the US FDA lifted a clinical hold imposed list year.
Pop Test Abuse Deterrent Technologies has received a patent for an opioid drug delivery and abuse deterrent ‘smart pill’ it says can prevent death, theft, diversion and counterfeiting.
Cure Pharmaceutical has submitted a patent application for an oral film delivery technology it says can combine several active pharmaceutical ingredients without negative interaction.
Non-profit organisations have challenged the proposed addition of long-acting insulin analogues to the World Health Organisation’s Model List of Essential Medicines, citing price as a key factor.
The University of Birmingham has developed a cell-penetrating peptide it claims could be used to make eye drop versions of age-related macular degeneration drugs currently delivered by injection.
Merck & Co and Aduro Biotech have announced plans to test Keytruda combined with CRS-207 in patients suffering malignant pleural mesothelioma as a result of exposure to asbestos.
Long life-cycles and significant consolidation in the manufacturing space have led to a lack of skilled workers in the vaccine space, says Sanofi Pasteur.
Aptar Pharma has acquired 20% of the US-based company, Kali Care, less than two months after inaugurating its first facility outside of France as it aims to expand globally.
Ibuprofen patch developer Medherant Ltd. has hired France-based contractor Laboratoires Plasto Santé (LPS) to make the product for clinical trials due to start this year.
Brineura's $702,000 (€640,000) a-year price tag reflects production costs and investment in tech used to administer the enzyme replacement therapy to the brain says BioMarin Pharmaceuticals.
Vaxart says its tablet delivery platform has simplified vaccine production so significantly it may bring manufacturing currently contracted to Lonza back in-house.
Sanofi Pasteur says heavy investment in messenger RNA (mRNA) is warranted as such technology could revolutionise vaccine development and manufacturing.
Partnering and collaborating to advance drug delivery innovation is essential, now more than ever, say industry experts from Boehringer-Ingelheim and Merck.
Arecor has entered a £45m ($56m) agreement to develop once daily injection of Cadila Pharmaceuticals’ basal insulin product using its reformulation technology.
Ohr Pharmaceutical has raised enough money to complete a Phase III trial of its AMD drug - Squalamine – just days after NASDAQ officials gave it 180 days to regain the exchange’s minimum listing price.
Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.
The US FDA has accepted a manufacturing and trial plan for Evoke Pharma's Gimoti, the nasal metoclopramide formulation that fell short in a Phase III trial last year.
Mylan has recalled batches of its EpiPen in the US over concerns the auto-injector device made by Pfizer’s Meridian Medical Technologies unit is faulty.
Alexion Pharmaceuticals will use the LNP delivery licensed from Arbutus Biopharma as part of its messenger RNA therapeutics development partnership with Moderna Therapeutics.
Imprimis Pharmaceuticals says it is evaluating pursuing New Drug Application (NDA) status for some of its product reformulations through the US FDA 505(b)(2) development pathway.
